Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Good morning fellow longs (and trash posters)

<< Previous

Bullboard Posts

Next >>

Comment by GOBOGOHon Jul 10, 2020 10:19am

109 Views

Post# 31250983

RE:Good morning fellow longs (and trash posters)

Behstreet,

Do you know if the drug - repairs damaged lungs or helps prevent the damage from happening (ie, can it help in the earlier stages of Covid infections). If later is the case and can be proven then the stock would have great potential.

Thanks

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing